Drug Profile


Alternative Names: Amigal; Amigal-ERT combo therapy; AT 1001; Galafold; GR181413A; HGT-3310; Migalastat hydrochloride; migalastat-ERT combo therapy

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Amicus Therapeutics
  • Developer Amicus Therapeutics; GlaxoSmithKline
  • Class Imino sugars; Pharmacological chaperones; Piperidines; Small molecules
  • Mechanism of Action Alpha-galactosidase stimulants; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fabry's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 08 Mar 2017 Launched for Fabry's disease in Italy (PO)
  • 01 Mar 2017 Launched for Fabry's disease in United Kingdom (PO)
  • 14 Feb 2017 Additional data from the phase III FACETS trial in Fabry's disease released by Amicus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top